Recent Advances in the Development and Application of Radiolabeled Kinase Inhibitors for PET Imaging (Q26774478)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

1 reference

8 February 2021

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

author name string

Vadim Bernard-Gauthier

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

Justin J Bailey

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

Sheldon Berke

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

language of work or name

English

0 references

publication date

2015

0 references

9 December 2015

1 reference

8 February 2021

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

8 February 2021

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

page(s)

22000-22027

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

Creative Commons Attribution

13 May 2020

copyright license

1 reference

8 February 2021

0 references

Targeting cancer with small molecule kinase inhibitors

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

FDA-approved small-molecule kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

KLIFS: a knowledge-based structural database to navigate kinase-ligand interaction space.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Assessment of chemical coverage of kinome space and its implications for kinase drug discovery.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Current compound coverage of the kinome.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A new challenging and promising era of tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Protein kinases: evolution of dynamic regulatory proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Irreversible protein kinase inhibitors: balancing the benefits and risks

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Developing irreversible inhibitors of the protein kinase cysteinome

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Tinkering outside the kinase ATP box: allosteric (type IV) and bivalent (type V) inhibitors of protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Strategies for the selective regulation of kinases with allosteric modulators: exploiting exclusive structural features.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Clinical pharmacokinetics of tyrosine kinase inhibitors: implications for therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Mechanisms of drug resistance in kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Metabolic positron emission tomography imaging in cancer detection and therapy response

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Positron emission tomography molecular imaging for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The role of molecular imaging in modern drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

(18)F-FDG PET/CT for monitoring treatment responses to the epidermal growth factor receptor inhibitor erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The role of fluorine-18-fluorodeoxyglucose positron emission tomography in evaluating the response to tyrosine-kinase inhibitors in patients with metastatic primary renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Development of radiotracers for oncology--the interface with pharmacology

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET radiotracers: crossing the blood-brain barrier and surviving metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET imaging with small-molecule tyrosine kinase inhibitors: TKI-PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Features of selective kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Comprehensive analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Design and selection parameters to accelerate the discovery of novel central nervous system positron emission tomography (PET) ligands and their application in the development of a novel phosphodiesterase 2A PET ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A philosophy for CNS radiotracer design

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiolabeled small molecule protein kinase inhibitors for imaging with PET or SPECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

In vivo evaluation of the biodistribution of 11C-labeled PD153035 in rats without and with neuroblastoma implants.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Potential (18)F-labeled biomarkers for epidermal growth factor receptor tyrosine kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis of ML03, a novel positron emission tomography biomarker for targeting epidermal growth factor receptor via the labeling synthon: [11C]acryloyl chloride

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Evaluation of modified PEG-anilinoquinazoline derivatives as potential agents for EGFR imaging in cancer by small animal PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A fully automated two-step synthesis of an (18)F-labelled tyrosine kinase inhibitor for EGFR kinase activity imaging in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The quest to overcome resistance to EGFR-targeted therapies in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

[11C]Gefitinib ([11c]Iressa): radiosynthesis, in vitro uptake, and in vivo imaging of intact murine fibrosarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Automated synthesis of [18F]gefitinib on a modular system.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Multidrug transporter ABCG2 prevents tumor cell death induced by the epidermal growth factor receptor inhibitor Iressa (ZD1839, Gefitinib).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Discovery and Evaluation of Clinical Candidate AZD3759, a Potent, Oral Active, Central Nervous System-Penetrant, Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

In vivo evaluation of P-glycoprotein and breast cancer resistance protein modulation in the brain using [(11)C]gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

21 January 2018

Erlotinib hydrochloride

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Quantitative analysis of [11C]-erlotinib PET demonstrates specific binding for activating mutations of the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET imaging of patients with non-small cell lung cancer employing an EGF receptor targeting drug as tracer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Erlotinib accumulation in brain metastases from non-small cell lung cancer: visualization by positron emission tomography in a patient harboring a mutation in the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Breast Cancer Resistance Protein and P-Glycoprotein Influence In Vivo Disposition of 11C-Erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A comparative PET imaging study with the reversible and irreversible EGFR tyrosine kinase inhibitors [(11)C]erlotinib and [(18)F]afatinib in lung cancer-bearing mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Development of [18F]afatinib as new TKI-PET tracer for EGFR positive tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Strategies for discovering and derisking covalent, irreversible enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Assessment of 11C-labeled-4-N-(3-bromoanilino)-6,7-dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET-based biodistribution and radiation dosimetry of epidermal growth factor receptor-selective tracer 11C-PD153035 in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Molecular imaging with 11C-PD153035 PET/CT predicts survival in non-small cell lung cancer treated with EGFR-TKI: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Metabolism of epidermal growth factor receptor targeting probe [11C]PD153035: impact on biodistribution and tumor uptake in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A pilot study on EGFR-targeted molecular imaging of PET/CT With 11C-PD153035 in human gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Lapatinib access into normal brain and brain metastases in patients with Her-2 overexpressing breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The role of efflux and uptake transporters in [N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine (GW572016, lapatinib) disposition and drug interactions.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Development of a new epidermal growth factor receptor positron emission tomography imaging agent based on the 3-cyanoquinoline core: Synthesis and biological evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline for the imaging of epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Molecular imaging of active mutant L858R EGF receptor (EGFR) kinase-expressing nonsmall cell lung carcinomas using PET/CT

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Molecular imaging of nonsmall cell lung carcinomas expressing active mutant EGFR kinase using PET with [(124)i]-morpholino-IPQA

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The first radiosynthesis of [(11)C]AZD8931 as a new potential PET agent for imaging of EGFR, HER2 and HER3 signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Metabolic stability of 6,7-dialkoxy-4-(2-, 3- and 4-[18F]fluoroanilino)quinazolines, potential EGFR imaging probes

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiohalogenated 4-anilinoquinazoline-based EGFR-TK inhibitors as potential cancer imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine⁷⁹⁰ → methionine⁷⁹⁰ mutant.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Novel hybrids of (phenylsulfonyl)furoxan and anilinopyrimidine as potent and selective epidermal growth factor receptor inhibitors for intervention of non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Noncovalent Mutant Selective Epidermal Growth Factor Receptor Inhibitors: A Lead Optimization Case Study

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Novel mutant-selective EGFR kinase inhibitors against EGFR T790M

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Polypharmacology - foe or friend?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A tyrosine kinase inhibitor-based high-affinity PET radiopharmaceutical targets vascular endothelial growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Visualization of angiogenesis during cancer development in the polyoma middle T breast cancer model: molecular imaging with (R)-[11C]PAQ

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

[¹¹C]Sorafenib: radiosynthesis and preclinical evaluation in tumor-bearing mice of a new TKI-PET tracer

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis, in silico, in vitro, and in vivo investigation of 5-[¹¹C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Labeled 3-aryl-4-indolylmaleimide derivatives and their potential as angiogenic PET biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

PET molecular imaging of angiogenesis with a multiple tyrosine kinase receptor-targeted agent in a rat model of myocardial infarction.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Rhenium and technetium complexes bearing quinazoline derivatives: progress towards a 99mTc biomarker for EGFR-TK imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

High tumor uptake of (64)Cu: implications for molecular imaging of tumor characteristics with copper-based PET tracers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis and positron emission tomography studies of carbon-11-labeled imatinib (Gleevec).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

(124)I-iodopyridopyrimidinone for PET of Abl kinase-expressing tumors in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

In vivo imaging of Bcr-Abl overexpressing tumors with a radiolabeled imatinib analog as an imaging surrogate for imatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Imatinib analogs as potential agents for PET imaging of Bcr-Abl and c-KIT expression at a kinase level

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis and biological evaluation of a fluorine-18 derivative of dasatinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Dosimetry of 18F-labeled tyrosine kinase inhibitor SKI-249380, a dasatinib-tracer for PET imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Fluorine-labeled dasatinib nanoformulations as targeted molecular imaging probes in a PDGFB-driven murine glioblastoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Positron emission tomography image-guided drug delivery: current status and future perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Syntheses and evaluation of carbon-11- and fluorine-18-radiolabeled pan-tropomyosin receptor kinase (Trk) inhibitors: exploration of the 4-aza-2-oxindole scaffold as Trk PET imaging agents

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

5-(4-((4-[(18)F]Fluorobenzyl)oxy)-3-methoxybenzyl)pyrimidine-2,4-diamine: a selective dual inhibitor for potential PET imaging of Trk/CSF-1R.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

In vivo positron emission tomography (PET) imaging of mesenchymal-epithelial transition (MET) receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Fluorine-18 radiolabeling and radiopharmacological characterization of a benzodioxolylpyrimidine-based radiotracer targeting the receptor tyrosine kinase EphB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

TRKing down an old oncogene in a new era of targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

BRAF as a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Pim kinases in cancer: diagnostic, prognostic and treatment opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Aurora Kinases and Potential Medical Applications of Aurora Kinase Inhibitors: A Review

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The mTOR pathway: a new target in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Design of glycogen synthase kinase-3 inhibitors: an overview on recent advancements.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Rationally designed PKA inhibitors for positron emission tomography: Synthesis and cerebral biodistribution of N-(2-(4-bromocinnamylamino)ethyl)-N-[11C]methyl-isoquinoline-5-sulfonamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The first design and synthesis of [11C]MKC-1 ([11C]Ro 31-7453), a new potential PET cancer imaging agent

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis and ex vivo evaluation of carbon-11 labelled N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea ([11C]AR-A014418): a radiolabelled glycogen synthase kinase-3beta specific inhibitor for PET studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Towards the preparation of radiolabeled 1-aryl-3-benzyl ureas: Radiosynthesis of [(11)C-carbonyl] AR-A014418 by [(11)C]CO(2) fixation

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

11CO2 fixation: a renaissance in PET radiochemistry.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β)

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis and preliminary PET evaluation of glycogen synthase kinase 3β (GSK-3β) inhibitors containing [(11)C]methylsulfanyl, [(11)C]methylsulfinyl or [(11)C]methylsulfonyl groups

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The first synthesis of [(11)C]SB-216763, a new potential PET agent for imaging of glycogen synthase kinase-3 (GSK-3).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis of N-[(11)C]-methyl-hydroxyfasudil as a new potential PET radiotracer for rho-kinases (ROCKs).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Evaluation of Rho-kinase activity in mice brain using N-[11C]methyl-hydroxyfasudil with positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis and radiopharmacological evaluation of cyclin-dependent kinase 4 (Cdk4) inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

[(11)C-carbonyl]CEP-32496: radiosynthesis, biodistribution and PET study of brain uptake in P-gp/BCRP knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237).

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis of 2,6-difluoro-N-(3-[11C]methoxy-1H-pyrazolo[3,4-b]pyridine-5-yl)-3-(propylsulfonamidio)benzamide as a new potential PET agent for imaging of B-Raf(V600E) in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

[11C]GSK2126458 and [18F]GSK2126458, the first radiosynthesis of new potential PET agents for imaging of PI3K and mTOR in cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Radiosynthesis of [18F]ATPFU: a potential PET ligand for mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis of carbon-11-labeled 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine derivatives as new potential PET tracers for imaging of p38α mitogen-activated protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis of (Z)-2-((1H-indazol-3-yl)methylene)-6-[¹¹C]methoxy-7-(piperazin-1-ylmethyl)benzofuran-3(2H)-one as a new potential PET probe for imaging of the enzyme PIM1.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Synthesis of [11C]CX-6258 as a new PET tracer for imaging of Pim kinases in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Selectively nonselective kinase inhibition: striking the right balance

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

A guide to picking the most selective kinase inhibitor tool compounds for pharmacological validation of drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Maximizing diversity from a kinase screen: identification of novel and selective pan-Trk inhibitors for chronic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

The kinetics of binding to p38MAP kinase by analogues of BIRB 796.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Small molecule substrate phosphorylation site inhibitors of protein kinases: approaches and challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.3390/MOLECULES201219816

Trk receptors: roles in neuronal signal transduction

21 January 2018

1 reference

12 December 2020

Synthesis of [11C]Iressa as a new potential PET cancer imaging agent for epidermal growth factor receptor tyrosine kinase

1 reference

12 December 2020

The tyrosine kinase inhibitor PD153035: implication of labeling position on radiometabolites formed in vitro

1 reference

12 December 2020

The effect of the [18F]-PEG group on tracer qualification of [4-(phenylamino)-quinazoline-6-YL]-amide moiety--an EGFR putative irreversible inhibitor

1 reference

12 December 2020

Further characterization of the epidermal growth factor receptor ligand 11C-PD153035.

1 reference

12 December 2020

[11C]enzastaurin, the first design and radiosynthesis of a new potential PET agent for imaging of protein kinase C

1 reference

12 December 2020

[11C]sorafenib: radiosynthesis and preliminary PET study of brain uptake in P-gp/Bcrp knockout mice

1 reference

12 December 2020

The dynamics of drug-target interactions: drug-target residence time and its impact on efficacy and safety

1 reference

12 December 2020

PD153035, a tyrosine kinase inhibitor, prevents epidermal growth factor receptor activation and inhibits growth of cancer cells in a receptor number-dependent manner

1 reference

12 December 2020

https://api.crossref.org/works/10.3390/MOLECULES201219816

1 reference

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.3390/MOLECULES201219816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

release_q6zrowx5rfg7xfr7xl2fopx5vi

13 May 2020

Fatcat ID

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json

13 May 2020

PubMed publication ID

26690113

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6332294&resulttype=core&format=json